These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38256334)

  • 1. Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.
    Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
    [No Abstract]   [Full Text] [Related]  

  • 2. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
    Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
    Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
    Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
    Wu J; Wei Y; Pan J; Jin S; Gu W; Gan H; Zhu Y; Ye DW
    Int J Cancer; 2021 Feb; 148(3):673-681. PubMed ID: 33006389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
    Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
    Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary DNA as a Tool for Germline and Somatic Mutation Detection in Castration-Resistant Prostate Cancer Patients.
    Januskevicius T; Sabaliauskaite R; Dabkeviciene D; Vaicekauskaite I; Kulikiene I; Sestokaite A; Vidrinskaite A; Bakavicius A; Jankevicius F; Ulys A; Jarmalaite S
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
    Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
    Wu Y; Yu H; Zheng SL; Na R; Mamawala M; Landis T; Wiley K; Petkewicz J; Shah S; Shi Z; Novakovic K; McGuire M; Brendler CB; Ding Q; Helfand BT; Carter HB; Cooney KA; Isaacs WB; Xu J
    Prostate; 2018 Jun; 78(8):607-615. PubMed ID: 29520813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
    Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
    Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
    JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.